Drug Trial Radar · NCT02690207
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
Last checked: Nov 20, 2026Latest source record: Mar 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,687
Actual
Start
Mar 16, 2016
Primary completion
Mar 15, 2019
Study completion Mar 15, 2019
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).
Conditions
- Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173ABiological
Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)Time frame: During 30 days (Days 0-29) after any vaccination (across doses)
- Number of Subjects With Any and Related Serious Adverse Events (SAEs)Time frame: From Month 0 until study end (Month 14, i.e. 12 months post dose 2)
- Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)Time frame: From Month 0 until study end (Month 14, i.e. 12 months post dose 2)
Locations
195 sites in 18 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Spring Valley, California
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Meridian, Idaho
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Columbia, Maryland
GSK Investigational Site
Elkridge, Maryland
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Somers Point, New Jersey
GSK Investigational Site
Cary, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Hickory, North Carolina
GSK Investigational Site
Salisbury, North Carolina
GSK Investigational Site
Wilmington, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Wadsworth, Ohio
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Uniontown, Pennsylvania
GSK Investigational Site
Greer, South Carolina
GSK Investigational Site
Mt. Pleasant, South Carolina
GSK Investigational Site
Bristol, Tennessee
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Murray, Utah
GSK Investigational Site
Newport News, Virginia
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Winchester, Virginia
GSK Investigational Site
Renton, Washington
GSK Investigational Site
Maroubra, New South Wales, Australia
GSK Investigational Site
Umina, New South Wales, Australia
GSK Investigational Site
Westmead, New South Wales, Australia
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.